CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 716 enrolled
Drug / intervention
Oseltamivir +1 moredrug
Likely dose
Oseltamivir 75 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01314911
NCT01314911N/ACompleted
CompareCT.gov

A Randomized Double-Blind Study Comparing Oseltamivir Versus Placebo for the Treatment of Influenza in Low Risk Adults

National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Mar 15, 2011·Updated Feb 5, 2019

In Brief

A clinical study evaluating Oseltamivir and Placebo for Influenza, Human. Completed, enrolled 716 participants across 51 sites in 3 countries.

Detailed Summary

People who are infected with the influenza virus may develop respiratory illnesses, such as pneumonia, or other life-threatening complications. Currently, there are four antiviral medications that are used to treat influenza. This study will examine one of these medications, oseltamivir, to examine how it affects the shedding of influenza virus in infected people.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza, Human
CountriesArgentina, Thailand, United States
Collaborators--

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMar 15, 2011
Enrollment StartApr 1, 2011
Primary CompletionNov 18, 2017
TodayJul 2, 2026
Enrollment to primary: 6.6 yearsPosted 15.3 years ago

Interventions

Oseltamivirdrug

Subjects were prescribed Oseltamivir twice daily for 5 days, and each dose consisted of one capsule of Oseltamivir 75 mg.

Placebodrug

Subjects were prescribed the matching placebo twice daily for 5 days, and each dose consisted of one capsule of placebo.